Incyte | INCY - Selling And Administration Expenses

Stock Price
95.96
Daily Change
1.66 1.76%
Monthly
-2.15%
Yearly
53.63%
Q2 Forecast
87.59

Incyte reported $390.41M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Agenus USD 10.56M 13.04M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Exelixis USD 123.02M 19.9M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Merck USD 2.85B 215M Dec/2025
Moderna USD 308M 40M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Novartis USD 3.44B 132M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025